Tilly Bingham

Tilly BinghamTilly (Matilda) Bingham is a drug discoverer with over 20 years' experience of working in the pharmaceutical R&D sector in 'large pharma' (Organon, Schering-Plough, MSD), Biotech (Redx Pharma), CRO (Concept Life Sciences) and is currently Executive i Residence at Cumulus Oncology. Tilly's early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier for targets including the GPCRs OX2R, V1R and CGRP. Then, as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical candidates, including the clinical candidate porcupine inhibitors RXC004 (oncology), RXC006 (AZD5055, fibrosis), Pan RAF inhibitor (JZP815) and FDA approved BTK inhibitor Pirtobrutinib. As VP Science and Chief Scientific Officer at the UK CRO Concept Life Sciences she oversaw multiple research programmes and the development of new research capability across the group. In her current role as Executive in Residence at Cumulus Oncology Tilly is employing her significant expertise in pre-clinical drug discovery to accelerate oncology innovation to key value inflection points. Read More Read Less

2 results found
List viewGrid view
Sort By:
1.
Progress in Medicinal ChemistryNR
Publisher: Elsevier Science
No Review Yet
₹14,205
Binding:
Hardback
Release:
01 Nov 2024
Language:
English
International Edition
Ships within 18-20 Days Explain..
Free Shipping in India and low cost Worldwide.
2.
Progress in Medicinal Chemistry9 % NR
International Edition
Ships within 18-20 Days Explain..
Free Shipping in India and low cost Worldwide.
No more records found